X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agitation disorder, etc.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: Pink Kush
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Iran Expo
Not Confirmed
Contact SupplierDetails:
Pink Kush (delta-9 tetrahydrocannabinol) is a CB2/CB1 receptor partial agonist, which is approved in combination with Cannabigerol for the treatment of stress, pain and depression.
Lead Product(s): Tetrahydrocannabinol,Cannabigerol
Therapeutic Area: Psychiatry/Psychology Product Name: Pink Kush
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Iran Expo
Not Confirmed
Contact Supplier
Details:
MediPharmto design, manufacture and supply a liquid oral cannabis study drug for the Phase 2 Life’s end Benefits of cannabidiol and tetrahydrocannabinol (LiBBY) study, to be conducted in the U.S., across 20 sites, to treat hospice-eligible patients diagnosed with dementia and agitation.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: T2:C100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $16.0 million Upfront Cash: Undisclosed
Deal Type: Funding August 09, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
Three initial proposed clinical trials will evaluate the effectiveness of proprietary THC and CBD (cannabidiol) drug candidates for multiple indications including Pain, Insomnia associated with Major Depression, and Uremic Pruritus.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol
Therapeutic Area: Sleep Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: McMaster University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 21, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
Patients in Germany are now able to access GMP-certified quality medical cannabis from STADA through local pharmacies under the brand – CannabiSTADA, distributed through STADAPHARM, a direct subsidiary of STADA.
Lead Product(s): Tetrahydrocannabinol,Cannabidiol
Therapeutic Area: Neurology Product Name: CannabiSTADA
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: European Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 01, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
As a result of agreement, patients in Germany are now able to access GMP-certified quality medical cannabis from STADA through local pharmacies under the brand – CannabiSTADA (cannabidiol), distributed through STADAPHARM, a direct subsidiary of STADA.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol
Therapeutic Area: Gastroenterology Product Name: CannabiStada
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: STADA Arzneimittel
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 01, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
IGC-AD1 (tetrahydrocannabinol) is a small molecule drug that targets neuroinflammation and CB1 receptor dysfunction. It is being evaluated for the treatment of alzheimer disease.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: IGC-AD1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Details:
The net proceeds will be used for the advancement of company's investigational medicines including IGC-AD1, a natural THC-based oral formulation, as a treatment for agitation in dementia from Alzheimer’s disease.
Lead Product(s): Tetrahydrocannabinol,Melatonin
Therapeutic Area: Neurology Product Name: IGC-AD1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bradbury Asset Management
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 26, 2024
Details:
The acquisition expands Branded Legacy's portfolio ranging from gummies to compression sleeves and pain-relieving topical creams, including Relief Gummy, which contains a balanced ratio of CBD to Nano Delta-9-THC.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: Relief Gummy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Branded Legacy, Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 12, 2024
Details:
The company is aiming to concentrate on the clinical advancement of THC:CBD (Tetrahydrocannabinol), a partial agonist of the CB1 receptor with Cannabidiol. Both controlled substances will undergo evaluation for the treatment of chemotherapy-induced neuropathic pain.
Lead Product(s): Tetrahydrocannabinol,Cannabidiol
Therapeutic Area: Neurology Product Name: THC:CBD
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: German Pain Association
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 23, 2024
Details:
IGC-AD1, a combination medicine with a CB1 receptor partial agonist with anti-neuroinflammatory properties. It is under phase 2 clinical development for the treatment of dementia due to Alzheimer’s.
Lead Product(s): Tetrahydrocannabinol,Melatonin
Therapeutic Area: Neurology Product Name: IGC-AD1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2024
Details:
The company will use the proceeds for developing its proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids.
Lead Product(s): Cannabidiol,Cannabigerol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: RHO Phyto
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $0.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 04, 2023
Details:
Trichomylin softgels, a first-in-class drug product candidate formulated with a proprietary fixed-dose cannabinoid combination, has been specifically designed for the management of chronic pain.
Lead Product(s): Cannabidiol,Cannabichromene,Tetrahydrocannabinol
Therapeutic Area: Musculoskeletal Product Name: Trichomylin
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2023
Details:
SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS and inhibit the degradation of endocannabinoids in order to improve uptake of THC.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2023
Details:
SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS and inhibit the degradation of endocannabinoids in order to improve uptake of THC.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2023
Details:
The initial services relate to ResolutionRx’s repurposing of dronabinol and its development program for obstructive sleep apnea pursuant to which Ab Initio will, among other things, manufacture and test the new dronabinol lipid nanoparticle formulation for pharmacokinetic.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Sleep Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ResolutionRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 12, 2023
Details:
SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS and inhibit the degradation of endocannabinoids in order to improve uptake of THC.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
Under the agreement, ResolutionRx will use and exploit the Licensed IP associated with new dronabinol formulations initially to be developed for the treatment of obstructive sleep apnea.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Sleep Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ResolutionRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 09, 2023
Details:
The company will use the proceeds for developing its proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids.
Lead Product(s): Cannabidiol,Cannabigerol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: RHO Phyto
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $1.4 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 02, 2023
Details:
IGC-AD1, a low-dose tetrahydrocannabinol based formulation, currently in Phase 2 of clinical trials as a potential treatment for agitation in dementia due to alzheimer’s.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: IGC-AD1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2023
Details:
The proceeds will be used for production, raw material and laboratory costs associated with production of GMP cannabinoid medicines CannEpil, a high-CBD, low-THC formulation delivered by an oral mucosal solution and CogniCann, an oral spray that combines THC and CBD.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: CannEpil
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oberon Capital
Deal Size: $2.6 million Upfront Cash: Undisclosed
Deal Type: Financing August 01, 2023
Details:
Fortrea will manage Incannex's IND opening Phase 2/3 clinical trial investigating IHL-42X which is a synergistic composition of dronabinol, a synthetic form of Tetrahydrocannabinol, and acetazolamide, a carbonic anhydrase inhibitor, for treatment of obstructive sleep apnoea.
Lead Product(s): Acetazolamide,Tetrahydrocannabinol
Therapeutic Area: Sleep Product Name: IHL-42X
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Incannex Healthcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 18, 2023
Details:
The funding will support IGC’s working capital needs primarily related to its Alzheimer’s research, with IGC-AD1, a low-dose tetrahydrocannabinol based formulation, currently in Phase 2 of clinical trials as a potential treatment for agitation in dementia due to Alzheimer’s.
Lead Product(s): Tetrahydrocannabinol,Melatonin
Therapeutic Area: Neurology Product Name: IGC-AD1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: O-Bank Co., Ltd.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing July 07, 2023
Details:
The funds will support the advancement of the Company’s Phase-2 clinical trial of IGC-AD1 (tetrahydrocannabinol), the Company’s promising investigational drug candidate designed to address agitation in dementia caused by Alzheimer's disease.
Lead Product(s): Tetrahydrocannabinol,Melatonin
Therapeutic Area: Neurology Product Name: IGC-AD1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bradbury Asset Management
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement July 06, 2023
Details:
SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS and inhibit the degradation of endocannabinoids in order to improve uptake of THC.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hannover Medical School
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2023
Details:
SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS and inhibit the degradation of endocannabinoids in order to improve uptake of THC.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2023
Details:
The collaboration aims to focus on Avicanna’s proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids.
Lead Product(s): Cannabidiol,Cannabigerol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: RHO Phyto
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Applied Research Centre at Langara College
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 13, 2023
Details:
SBI-100 OE is a novel synthetically-derived molecule formulated as an eye-drop using a propriety nanoemulsion to improve delivery into the eye. It targets the CB1 receptor, which plays a key role in managing intraocular pressure associated with glaucoma.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Ophthalmology Product Name: SBI-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for alzheimer's disease and agitation to stimulate cannabinoid receptors across the CNS and inhibit the degradation of endocannabinoids in order to improve uptake of THC.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2023
Details:
SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for alzheimer's disease and agitation to stimulate cannabinoid receptors across the CNS and inhibit the metabolic degradation of endocannabinoids in order to improve uptake of THC.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
Details:
The objective of this clinical trial is to evaluate the efficacy, safety and tolerability of SciSparc's proprietary drug candidate SCI-110 (dronabinol) in adult patients (between 18 and 65 years of age) using daily oral treatment.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
ANEB-001 is a potent, small molecule cannabinoid receptor antagonist, to address the unmet medical need for a specific antidote for acute cannabinoid intoxication.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Psychiatry/Psychology Product Name: ANEB-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Details:
SCI-110 is a unique and proprietary combination of Dronabinol, an FDA-Approved, synthetic version of delta-9-tetrahydrocannabinol, and CannAmide™, the Company's proprietary formulation of Palmitoylethanolamide (PEA).
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2023
Details:
SCI-110, contains dronabinol with the endocannabinoid palmitoylethanolamide. It is designed to stimulate cannabinoid receptors across the CNS and inhibit the metabolic degradation of endocannabinoids in order to improve uptake of THC.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
D9-THC (dronabinol, D9-tetrahydrocannabinol) is an oral capsule drug product that is being tested for clinical efficacy in patients with obstructive sleep apnea (OSA).
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Sleep Product Name: D9-THC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Illinois
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 23, 2023
Details:
Dronabinol, delta-9-THC, is a synthetic version of the naturally occurring substance in the cannabis plant. Drug is an endocannabinoid CB1 and CB2 receptor agonist which is being developed for the treatment of Obstructive sleep apnea.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Sleep Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2023
Details:
NanaBis™ (tetrahydrocannabinol) is an investigative novel analgesic for cancer patients comprising equal parts of CBD and THC encapsulated in Medlab’s patented delivery platform, NanoCelle®. NanaBis™ is applied to the oro-buccal membrane for rapid uptake.
Lead Product(s): Tetrahydrocannabinol,Cannabidiol
Therapeutic Area: Neurology Product Name: NanaBis
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2023
Details:
SCI-110 is a unique and proprietary combination of Dronabinol, an FDA-Approved, synthetic version of delta-9-tetrahydrocannabinol, and CannAmide™, the Company's proprietary formulation of Palmitoylethanolamide (PEA).
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Soroka Medical Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 09, 2023
Details:
REDUVO™ is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV). It is also used to treat weight loss and severe nausea in people living with HIV infection.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Gastroenterology Product Name: Reduvo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2022
Details:
The relationship expands Reakiro’s product portfolio from CBD food supplements and cosmetics to include medicinal cannabis products that can be supplied on a prescription basis by pharmacies, clinics, and hospitals globally.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: Estratt
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: A2W Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 21, 2022
Details:
REDUVO™ (dronabinol) is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV). It is also used to treat weight loss and severe nausea in people living with HIV infection.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Gastroenterology Product Name: Reduvo
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2022
Details:
SCI-110 is a unique and proprietary combination of Dronabinol, an FDA-Approved, synthetic version of delta-9-tetrahydrocannabinol (Δ⁹-THC), and CannAmide™, the Company’s proprietary formulation of Palmitoylethanolamide.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
This is a phase I Multiple Ascending Dose (MAD) study to evaluate safety and tolerability of IGC-AD1 (tetrahydrocannabinol) in subjects with AD. Twelve subjects will be enrolled. Three different ascending doses of the study product will be given: low, medium and high doses.
Lead Product(s): Tetrahydrocannabinol,Melatonin
Therapeutic Area: Neurology Product Name: IGC-AD1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
SBI-100 (tetrahydrocannabinol) OE, a proprietary, synthetic cannabinoid derivative possessing a novel molecular structure and formulation that was rationally designed to enable better penetration of ocular tissue and effective topical delivery of a CB1R agonist.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Ophthalmology Product Name: SBI-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Details:
ABO’s financing facility, to be used at the option of Tetra Bio-Pharma, allows the Company to finance the manufacturing costs of its QIXLEEF (cannabidiol) drug candidate.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: Qixleef
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alpha Blue Ocean
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Financing September 14, 2022
Details:
The company intends to use the net proceeds of the Financing to finance the manufacturing costs of its Qixleef (cannabidiol) drug candidate, to repay indebtedness and for working capital.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: Qixleef
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alpha Blue Ocean
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 08, 2022
Details:
RespireRx’s ResolutionRx business unit is developing dronabinol, ∆-9-THC, a synthetic version of the naturally occurring substance in the cannabis plant, for the treatment of OSA.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Sleep Product Name: ResolutionRx
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
The primary safety objective of the trial will be to assess absolute and relative frequencies of serious adverse events for the entire population and separately for the SCI-110 (dronabinol) and placebo groups.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Yale University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 01, 2022
Details:
THC stands for Delta-9 tetrahydrocannabinol or tetrahydrocannabinol-9 which is a cannabinoid molecule found in the Cannabis Sativa plant and tends to deliver psychoactive effects- that make people high.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Psychiatry/Psychology Product Name: Delta-9 Gummy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
Psilly™ branded functional fungi-based products will be developed by Avicanna utilizing Avicanna’s proprietary delivery systems and scientific platform.
Lead Product(s): Tetrahydrocannabinol,Cannabidiol
Therapeutic Area: Psychiatry/Psychology Product Name: Psilly
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ei.Ventures
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 20, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Medipharm is a full-service pharmaceutical company delivering high-quality, innovative Cannabis concentrate-based products & services.
